These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

221 related items for PubMed ID: 16931217

  • 1. Results of a randomized crossover study comparing once-daily and thrice-daily sevelamer dosing.
    Fischer D, Cline K, Plone MA, Dillon M, Burke SK, Blair AT.
    Am J Kidney Dis; 2006 Sep; 48(3):437-44. PubMed ID: 16931217
    [Abstract] [Full Text] [Related]

  • 2. A randomized, parallel, open-label study to compare once-daily sevelamer carbonate powder dosing with thrice-daily sevelamer hydrochloride tablet dosing in CKD patients on hemodialysis.
    Fishbane S, Delmez J, Suki WN, Hariachar SK, Heaton J, Chasan-Taber S, Plone MA, Moe S.
    Am J Kidney Dis; 2010 Feb; 55(2):307-15. PubMed ID: 20042256
    [Abstract] [Full Text] [Related]

  • 3. RenaGel efficacy in severe secondary hyperparathyroidism.
    Castro R, Herman A, Ferreira C, Travassos F, Nunes-Azevedo J, Oliveira M.
    Nefrologia; 2002 Feb; 22(5):448-55. PubMed ID: 12497746
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and side-effect profile of sevelamer hydrochloride used in combination with conventional phosphate binders.
    Sturtevant JM, Hawley CM, Reiger K, Johnson DW, Campbell SB, Burke JR, Bofinger A, Isbel NM.
    Nephrology (Carlton); 2004 Dec; 9(6):406-13. PubMed ID: 15663645
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Effect of sevelamer on mineral and lipid abnormalities in hemodialysis patients.
    Hamida FB, Fatma LB, Barbouch S, Kaaroud H, Helal I, Hedri H, Abdallah TB, Maiz HB, Kheder A.
    Saudi J Kidney Dis Transpl; 2008 Mar; 19(2):183-8. PubMed ID: 18310864
    [Abstract] [Full Text] [Related]

  • 7. Does concomitant administration of sevelamer and calcium carbonate modify the control of phosphatemia?
    Ouellet G, Cardinal H, Mailhot M, Ste-Marie LG, Roy L.
    Ther Apher Dial; 2010 Apr; 14(2):172-7. PubMed ID: 20438539
    [Abstract] [Full Text] [Related]

  • 8. Comparison of efficacy of the phosphate binders nicotinic acid and sevelamer hydrochloride in hemodialysis patients.
    Ahmadi F, Shamekhi F, Lessan-Pezeshki M, Khatami MR.
    Saudi J Kidney Dis Transpl; 2012 Sep; 23(5):934-8. PubMed ID: 22982903
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and safety of sevelamer. Comparison with calcium carbonate in the treatment of hyperphosphatemia in hemodialysis patients.
    Shaheen FA, Akeel NM, Badawi LS, Souqiyyeh MZ.
    Saudi Med J; 2004 Jun; 25(6):785-91. PubMed ID: 15195212
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Effect of sevelamer on dyslipidemia and chronic inflammation in maintenance hemodialysis patients.
    Yamada K, Fujimoto S, Tokura T, Fukudome K, Ochiai H, Komatsu H, Sato Y, Hara S, Eto T.
    Ren Fail; 2005 Jun; 27(4):361-5. PubMed ID: 16060120
    [Abstract] [Full Text] [Related]

  • 12. Novel dosage forms and regimens for sevelamer-based phosphate binders.
    Duggal A, Hanus M, Zhorov E, Dagher R, Plone MA, Goldberg J, Burke SK.
    J Ren Nutr; 2006 Jul; 16(3):248-52. PubMed ID: 16825030
    [Abstract] [Full Text] [Related]

  • 13. [Treatment with phosphate binder (sevelamer hydrochloride, calcium carbonate) based on PTH].
    Sato M, Fukazawa S, Yasuda T, Akatsuka T, Tozawa S, Niida Y, Hashimoto N, Mochizuki T, Koike T.
    Clin Calcium; 2005 Sep; 15 Suppl 1():23-8; discussion 28-9. PubMed ID: 16272625
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Comparison of sevelamer hydrochloride with colestimide, administered alone or in combination with calcium carbonate, in patients on hemodialysis.
    Itoh K, Tanaka M, Hashiguchi J, Funakoshi S, Nakano H, Kubo H, Kono T, Uchino J, Masaki K, Date T, Shigematsu T, Research Group for Future Hemodialysis.
    Ther Apher Dial; 2008 Apr; 12(2):126-32. PubMed ID: 18387160
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Sevelamer therapy for pediatric end-stage renal disease.
    Storms LE, Chicella MF, Dice JE.
    Pharmacotherapy; 2006 Mar; 26(3):410-3. PubMed ID: 16503722
    [Abstract] [Full Text] [Related]

  • 19. A randomized trial of sevelamer hydrochloride (RenaGel) with and without supplemental calcium. Strategies for the control of hyperphosphatemia and hyperparathyroidism in hemodialysis patients.
    Chertow GM, Dillon M, Burke SK, Steg M, Bleyer AJ, Garrett BN, Domoto DT, Wilkes BM, Wombolt DG, Slatopolsky E.
    Clin Nephrol; 1999 Jan; 51(1):18-26. PubMed ID: 9988142
    [Abstract] [Full Text] [Related]

  • 20. RenaGel, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone. The RenaGel Study Group.
    Slatopolsky EA, Burke SK, Dillon MA.
    Kidney Int; 1999 Jan; 55(1):299-307. PubMed ID: 9893140
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.